8-K: Profound Medical Launches AI-Powered BPH Module

Profound Medical Corp. announced the launch of its TULSA-AI Volume Reduction module for benign prostatic hyperplasia, significantly expanding its market potential.

Summary

• Profound Medical Corp. is launching its TULSA-AI Volume Reduction module at the Radiological Society of North America (RSNA) meeting from November 30 to December 4, 2025.
• The new module is designed to optimize the treatment of benign prostatic hyperplasia (BPH), or enlarged prostate, using AI-powered, MRI-guided, incision-free therapy.
• It aims to streamline workflow, reduce procedure times, and offer precision and customization for any prostate shape or size.
• The Company expects the module to increase adoption of the TULSA Procedure and triple its total available market in prostate disease to approximately 600,000 patients annually.
• New clinical data on TULSA-PRO for prostate cancer will also be presented at both the RSNA and Society for Urologic Oncology (SUO) meetings.

Sentiment

Score: 8

Explanation: The launch of a new AI-powered module for BPH, coupled with strong clinical data and a projected tripling of the total available market, represents a significant positive development for the company. The innovation addresses a large patient population with superior outcomes compared to current standards.

Positives

• Launch of TULSA-AI Volume Reduction module for BPH treatment, expanding the company's addressable market.
• Expected to triple Profound's total available market in prostate disease to about 600,000 patients annually.
• The TULSA Procedure offers significantly reduced risk of loss of sexual function and incontinence compared to traditional methods.
• CAPTAIN perioperative data demonstrates TULSA Procedure's superiority to Robotic Prostatectomy in blood loss, length of stay, post-op pain, and recovery time.
• AI integration streamlines workflow and reduces procedure times, making TULSA-PRO more efficient for healthcare providers.
• The TULSA Procedure is incision-free, radiation-free, requires no hospital stay, and allows for quick patient recovery.

Risks

• Risks inherent in the medical device industry.
• Uncertainties regarding regulatory approvals.
• Challenges related to reimbursement policies.
• Impact of general economic factors.
• Risks associated with equity markets.
• Risks related to growth and competition.
• Actual financial results may not be consistent with expectations, including revenue, operating expenses, and cash usage.
• Forward-looking statements may not occur by specified dates or at all.

Future Outlook

The Company anticipates that the TULSA-AI Volume Reduction module will significantly increase the adoption of the TULSA Procedure and expand its total available market in prostate disease to approximately 600,000 patients annually. Management expects reduced procedure times due to AI integration to drive this increased adoption.

Management Comments

• "We're confident to launch the TULSA-AI Volume Reduction module for BPH, following a successful pilot trial earlier this year." Arun Menawat, CEO and Chairman.
• "The use of AI to streamline the workflow and reduce procedure times is a significant advance that makes using TULSA-PRO for treating enlarged prostate just as efficient as other modern procedures, but with the advanced benefits of precision and customization to any prostate shape or size." Arun Menawat, CEO and Chairman.
• "We expect the reduced procedure times will increase adoption of the TULSA Procedure and triple Profound's total available market in prostate disease to about 600,000 patients annually." Arun Menawat, CEO and Chairman.

Industry Context

The launch of the TULSA-AI Volume Reduction module positions Profound Medical to address a significant and common condition (BPH) with an advanced, incision-free, and AI-enhanced solution. This innovation aims to disrupt traditional BPH treatments like TURP, which have remained largely unchanged for decades, by offering improved patient outcomes and operational efficiency for healthcare providers. The expansion into BPH treatment, alongside its existing prostate cancer applications, broadens Profound's competitive footprint in the urology market.

Comparison to Industry Standards

• The TULSA Procedure, using TULSA-PRO, is the only incision-free procedure for prostate cancer, BPH, and hybrid patients.
• Current BPH treatment, such as transurethral resection of the prostate (TURP), is largely unchanged over the past 100 years and is associated with higher rates of complications like bleeding, erectile dysfunction, loss of ejaculation, and longer hospital stays.
• CAPTAIN perioperative data demonstrates the TULSA Procedure's superiority to Robotic Prostatectomy in terms of reduced blood loss, shorter length of stay, less post-operative pain, and quicker recovery time.
• The TULSA Procedure significantly reduces the risk of loss of sexual function and incontinence compared to alternative methods.
• The TULSA-AI module makes the procedure as efficient as other modern procedures while offering advanced precision and customization.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share due to expanded market and product adoption, leading to positive share price movement.
• Patients: Access to an advanced, incision-free, and less invasive treatment option for BPH and prostate cancer with superior outcomes (reduced complications, faster recovery, preserved sexual function and continence).
• Healthcare Providers: Enhanced efficiency and streamlined workflow for prostate treatments, allowing for more cases per day with the same hardware and staff, potentially increasing adoption.
• Competitors: Increased competitive pressure from an innovative, AI-powered solution that offers significant advantages over traditional and robotic procedures.

Next Steps

• Demonstrations of the TULSA-AI Volume Reduction module at Booth #3153, South Hall A, RSNA meeting (Nov 30-Dec 4, 2025).
• Presentations of new TULSA-PRO data for prostate cancer at RSNA (Dec 1-2, 2025) and SUO (Dec 5, 2025).
• Continued commercialization of TULSA-PRO and Sonalleve.
• Early stages of exploring additional potential treatment markets for Sonalleve (e.g., non-invasive ablation of abdominal cancers, hyperthermia for cancer therapy).

Key Dates

Recommendation

The launch of the TULSA-AI Volume Reduction module for BPH is a transformative event for Profound Medical, significantly expanding its addressable market by an estimated 600,000 patients annually. This, combined with compelling clinical data demonstrating the TULSA Procedure's superiority over conventional and robotic methods in terms of patient outcomes, recovery, and reduced complications, positions the company for substantial growth and market penetration. The integration of AI to enhance efficiency and reduce procedure times further strengthens its competitive advantage. This strategic expansion into a large, underserved market with a differentiated, high-value technology warrants a strong buy recommendation for long-term investors.

Keywords

Profound Medical, TULSA-AI, BPH, Benign Prostatic Hyperplasia, Prostate Treatment, MRI-guided, Incision-free, Medical Device, Urology, Prostate Cancer, RSNA, SUO, AI-powered therapy